Search research articles
Contact Us
Filters
Showing results (61-70 of 122) with videos related to
Page
of 13
Sort By:
Leukemia & Lymphoma
|
April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy
Theodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.
Leukemia & Lymphoma
|
February 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation
John Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 25, 2019
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
Keith W Pratz, Michelle A Rudek, B Douglas Smith, et al.
Haematologica
|
June 11, 2026
Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study
Priyanka Fernandes, Sergiu Pasca, Tania Jain, et al.
Leukemia & Lymphoma
|
February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease
Khaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
Judith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Leukemia Research
|
September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
Jonathan A Webster, Raoul Tibes, Larry Morris, et al.
Blood
|
November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Jeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Leukemia Research
|
September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities
J Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Blood
|
December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
Mitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 122) with videos related to
Sort By:
Page
of 13
Leukemia & Lymphoma
|
April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy
Theodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.
Leukemia & Lymphoma
|
February 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation
John Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 25, 2019
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
Keith W Pratz, Michelle A Rudek, B Douglas Smith, et al.
Haematologica
|
June 11, 2026
Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study
Priyanka Fernandes, Sergiu Pasca, Tania Jain, et al.
Leukemia & Lymphoma
|
February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease
Khaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
Judith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Leukemia Research
|
September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
Jonathan A Webster, Raoul Tibes, Larry Morris, et al.
Blood
|
November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Jeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Leukemia Research
|
September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities
J Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Blood
|
December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
Mitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.
Page
of 13